- Group home
- You must register/login in order to post into this group.
Project Description
Background: For neovascular age-related macular degeneration (nAMD), the ideal treatment regimen has not been determined. To address patient outcomes and resource use, a “Treat and Extend regimen” was applied for anti-vascular endothelial growth factor (VEGF) in nAMD.
Approach: With a “Treat and Extend regimen,” the aim is to individualise and gradually increase treatment intervals without reducing visual outcomes (i.e. quarterly injections instead of monthly injections). The team tested two separate drug treatments with the regimen: Eylea and Lucentis.
Intended Benefits
Patient outcomes: Under the new regimen, patients have visual outcomes similar to the previous approach.
Environmental, Financial, Social: A modified “Treat and Extend” approach reduces treatment burden and decreases monitoring visits, which would decrease the time spent travelling and associated carbon emissions.
Potential Barriers
Challenges to implementing this system could be:
Key Aspects of the Project
This project focused on a change in treatment that could reduce resource usage and improve patient experience.
Sunderland Eye Infirmary